Anbio Biotechnology (NNNN) Cash & Current Investments (2023 - 2025)

Anbio Biotechnology has reported Cash & Current Investments for 3 years, with the latest figure at $11.9 million in Q4 2025.

• On a quarterly basis, Cash & Current Investments rose 1.19% year-over-year to $11.9 million in Q4 2025; TTM through Dec 2025 was $11.9 million, a 1.19% increase from a year earlier, with the FY2025 full-year figure at $11.9 million, up 1.19% from the prior year.
• Cash & Current Investments was $11.9 million for Q4 2025 at Anbio Biotechnology, down from $13.4 million in the prior quarter.
• The five-year high for Cash & Current Investments was $13.4 million in Q2 2025, with the low at $9.7 million in Q4 2023.
• Average Cash & Current Investments over 3 years is $11.7 million, with a median of $11.8 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments climbed 21.36% in 2024, then grew 1.19% in 2025.
• Over 3 years, Cash & Current Investments stood at $9.7 million in 2023, then advanced by 21.36% to $11.8 million in 2024, then grew by 1.19% to $11.9 million in 2025.
• The last three Cash & Current Investments figures came in at $11.9 million (Q4 2025), $13.4 million (Q2 2025), and $11.8 million (Q4 2024), per Business Quant data.